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METHODS TO IMPAIR HEMATOLOGIC
CANCER PROGENITOR CELLS AND
COMPOUNDS RELATED THERETO

phenotypically de?ned leukemic stem cell population that is

CONTINUING DATA

hierarchy that originates from a primitive hematopoietic

The present application claims the bene?t of priority to
US. Provisional Patent Application Nos. 60/187,123, ?led

myeloid leukemia progenitor cells With long-term prolifera

suf?cient to propagate leukemic blasts both in vitro and in
vivo in xenogeneic mouse models of human AML (Bonnet
D, et al., Human acute myeloid leukemia is organiZed as a

cell. Nat. Med. 1997, 3: 730—737; Blair A, et al., Most acute

tive ability in vitro and in vivo have the phenotype CD34

Mar. 6, 2000, and 60/227,295, ?led Aug. 24, 2000, the

(+)/CD71(—)/HLA-DR-. Blood 1998, 92: 4325—35;

disclosures of Which are incorporated by reference herein in

their entirety.

10

BACKGROUND OF THE INVENTION

1. Field of the Invention
The present invention is related to methods of impairing

progenitor hematologic cancer cells or treating hematologic

15

cancer by targeting a cell surface marker speci?c for pro
genitor hematologic cancer cells. The present invention is

human disease. Clearly, in order to achieve durable
remission, it Will be necessary to speci?cally ablate the
20

Stem cells are commonly found in a variety of mamma

lian tissue systems. While the criteria by Which such cells are
de?ned vary depending upon the speci?c context, tWo
properties are generally regarded as central features of stem
cell populations: (1) stem cells must exhibit some capacity
for self-replication or self-reneWal, and (2) stem cells must

25

therapeutic regimens. This observation is consistent With the
clinical pro?le frequently seen for AML, Wherein a majority
of patients can achieve apparent complete remission, but in
30

and hepatic systems (Lemischka I R. Clonal, in vivo behav
ior of the totipotent hematopoietic stem cell. Semin Immu
nol 1991, 3: 349—55; Morrison S J, et al., The biology of

most cases Will relapse (Schiller G J ., Treatment of resistant

disease. Leukemia 1998, 12 Suppl 1: S20—4; Paietta E.,
Classical multidrug resistance in acute myeloid leukemia.
35

Med Oncol 1997, 14: 53—60). If LSC’s are more refractile to
chemotherapy than blasts, it is attractive to propose that
surviving stem cells are a major contributing factor to

leukemic relapse. Thus, strategies that speci?cally target
progenitor leukemia cells may provide more effective treat
ment for leukemia patients. In 1997, Bonnet and Dick
described the phenotype for LSC’s as CD34+/CD38—

Science 2000, 287: 1433—8; and, Alison M, et al., Hepatic
stem cells. J Hepatol 1998, 29: 676—82). Thus, it is perhaps
not surprising that similar cells have recently been docu

1944—50), as Well as data from our group, suggest that
LSC’s are biologically distinct from more mature leukemic

blasts and may not be responsive to conventional chemo

Cells of this nature have been described for a number of

hematopoietic stem cells. Annu. Rev. Cell Dev. Biol. 1995,
11: 35—71; Robertson E 1., Using embryonic stem cells to
introduce mutations into the mouse germ line. Biol Reprod
1991, 44: 238—45; Gage F H., Mammalian neural stem cells.

primitive or progenitor LSC population. HoWever, previous
studies (Terpstra W, et al., Fluorouracil selectively spares
acute myeloid leukemia cells With long-term groWth abilities
in immunode?cient mice and in culture. Blood 1996, 88:

be capable of differentiating into appropriate lineages
(Potten C S: Stem Cells. London, Academic Press, 1997).

tissues including hematopoietic, embryonic, neural, muscle

Philadelphia-positive acute lymphoblastic leukemia. Blood
2000, 95: 1007—13; Blair A, et al. Lack of expression of
Thy-1 (CD90) on acute myeloid leukemia cells With long
term proliferative ability in vitro and in vivo. Blood 1997,
89: 3104—12). The concept of a leukemic stem cell (LSC)

becomes critically important in considering the etiology of

also related to a method for diagnosing hematologic cancer.

2. Background of the Invention

Cobaleda C, et al., A primitive hematopoietic cell is the
target for the leukemic transformation in human

40

(Bonnet D, et al., Human acute myeloid leukemia is orga

mented in the context of malignant populations (Bonnet D,

niZed as a hierarchy that originates from a primitive hemato

et al., Human acute myeloid leukemia is organiZed as a

poietic cell. Nat. Med. 1997, 3: 730—737). We report that the
IL-3 receptor alpha chain (CD123) is highly expressed on
leukemic but not normal CD34+/CD38— hematopoietic

hierarchy that originates from a primitive hematopoietic
cell. Nat. Med. 1997, 3: 730—737; Blair A, et al., Most acute

myeloid leukemia progenitor cells With long-term prolifera

45

tive ability in vitro and in vivo have the phenotype CD34

(+)/CD71(—)/HLA-DR-. Blood 1998, 92: 4325—35;
Cobaleda C, et al., A primitive hematopoietic cell is the
target for the leukemic transformation in human

Philadelphia-positive acute lymphoblastic leukemia. Blood

50

pounds that bind to the human CD123 molecule (CD123
ectopeptide), in the diagnosis and treatment of hematologic
55

cient to induce disease.

One example of neoplasia arising from malignant stem
cells has recently been documented in the hematopoietic
This
system
disease
in theiscase
characteriZed
of acute myelogenous
by prematureleukemia
arrest of myeloid

SUMMARY OF THE INVENTION
The present invention relates to a method of using com

2000, 95: 1007—13). Indeed, a stem cell is in some respects
the ideal target for malignant transformation in that rela

tively little biological change is required. Since stem cells
already possess the genetic programming necessary to be
highly proliferative and developmentally plastic, one can
imagine that relatively subtle perturbations might be suffi

cells. In vieW of this state of the art, there is a need in the art
to provide a diagnostic method for detecting leukemia at an
early stage, as Well as more effective methods of treating this
disease.

60

cancers (e.g., leukemias and malignant lymphoproliferative
disorders). The CD123 speci?c compounds and mimetics
have particular utility as pharmaceuticals and reagents for
the therapy of hematologic cancer or malignant disease
states and for the diagnosis of hematologic cancer disease
states. In one embodiment, the present invention provides a
method of impairing a hematologic cancer progenitor cell

comprising contacting the cell With a compound that selec

development and the subsequent accumulation of large

tively binds to CD123 in an amount effective to impair the

numbers of non-functional leukemic blasts. While leukemic

progenitor hematologic cancer cell. This contacting step

blast cells are often of clonal origin and display relatively
homogeneous features, it has been demonstrated that such
populations are organiZed in a hierarchical fashion, analo
gous to normal hematopoietic progenitors. Thus, there is a

65

may occur in various environments, including in vitro and in
vivo in the body of an animal, including a human.

Throughout this application, reference Will be made spe
ci?cally to leukemia in describing certain embodiments of

US 6,733,743 B2
3
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the present invention. However, it is understood that the
present invention is not limited to diagnosis and treatment of
leukemia or malignant lymphoproliferative disorders alone,

CD123 labeling in cells derived from normal bone marroW

(panel A) or primary AML peripheral blood (panel B) are
provided. The inset polygon in panel A (left dot plot)

but to any disease in Which the cancerous cells selectively

indicates the percentage of total bone marroW that is positive

express CD123, Which includes the genus of hematologic

for CD123 expression (7%). The smaller rectangular gate
indicates the proportion of total marroW strongly positive for
CD123 (1%). The center dot plot in panel A shoWs bone

cancer.

In one embodiment, the present invention is directed to a

marroW that Was enriched for CD34+ cells by selection on

method of detecting the presence of CD123 on, for example,
a leukemia progenitor cell. Thus, the invention is also
directed to a method of diagnosing leukemia. It is under

an immunoaf?nity column (see methods). The gates indicate
10

stood that by using a labeled ligand to bind to CD123, it is
possible to detect the presence of leukemia progenitor cells.
Thus, it is also possible to diagnose the likelihood of the
onset of leukemia in patients possessing such leukemic

progenitor cells expressing CD123. The CD123 binding

the primary AML specimen. M1 markers in the histograms
indicate expression levels that are higher than 99% of
15

ligand may be an antibody to CD123, or it may be any of a

Furthermore, the label can be chosen from any of a variety

of molecules, including, but not limited to, enZymatic
20

reporter of the presence of the ligand Which has bound to the
CD123 molecule. Examples of such labels include those that

are, for example, radioactive, ?uorescent, chemiluminescent
or absorbant-based, or a combination of the foregoing. In

one embodiment, an assay is provided for detecting the
presence of progenitor leukemia cells in a sample by detect
ing the presence of CD123 in the sample, Which may be

25

accomplished by introducing a compound that selectively

an engrafted specimen using antibodies that are speci?c to
human cells. Panel B shoWs the CD34 vs. CD123 pro?le of
35

the complementarity determining regions (CDR’s).
rier; and any one or more of the CD123 speci?c compounds
and mimetics described above.
In another set of embodiments, the present invention

the CD45+ gated human cell population. For each sample,
50,000 events Were analyZed.
FIG. 4 shoWs CD123 and CD131 immunoblot analysis of

primary AML specimens. Five primary AML samples Were
40

derived from peripheral blood and sorted to isolate the
CD34+ population, thus insuring a virtually pure leukemic

sample. In addition, the leukemic cell line TF-1 (TF-1) and
normal marroW CD34+ cells (normal CD34+) Were included
as controls. Lysates Were made from each population, sub

provides a method for the treatment of leukemia, comprising
administering to a human subject or other animal in need of
such treatment a therapeutically effective amount of the

mouse. Six Weeks post-transplant, bone marroW cells Were

isolated and analyZed for the presence of human (CD45+)
leukemic cells. PanelAshoWs the CD34 vs. CD45 pro?le of

of antibodies, of the binding pockets of the antibodies, or of

The present invention also provides pharmaceutical
preparations comprising a pharmaceutically acceptable car

populations. Five primary AML specimens Were labeled
With CD34, CD38, and CD123 and analyZed by How cytom
etry. The ?gure shoWs CD123 labeling for the CD34+/
CD38- gated populations from each sample. The dark
sections indicate CD123 staining and the light sections
indicate parallel labeling With an isotype control antibody.
M1 markers in the histograms indicate expression levels that
are higher than 99% of isotype control samples. For each
specimen, 50,000—100,000 events Were analyZed.
AML cells Were transplanted into an irradiated NOD/SCID

30

the compounds such as peptides, antibodies, carbohydrates,
lipids or nucleic acids that bind to CD123, and in the case

000 events Were analyZed.

FIGS. 3A and 3B shoW engraftment of CD123+ AML
cells in NOD/SCID mice. Sorted CD34+/CD123+ primary

binds to CD123 and determining Whether the compound
binds to a component of the sample.
In another series of embodiments, the present invention
also provides compounds or molecules Which mimic
(mimetics) the three-dimensional structure of part or all of

isotype control samples. For each specimen, 50,000—100,
FIG. 2 shoWs CD123 expression on ?ve primitive AML

variety of molecules that speci?cally bind to CD 123.

compounds, or non-enZymatic compounds that serve as a

the total CD34+ population and the CD34+/CD38- popu
lation. The histograms indicate the CD123 labeling for the
tWo gated populations. Panel B shoWs the same analysis for

ject to denaturing PAGE and analyZed by immunoblot With
45

an anti-CD 123 antibody (top panel) or an anti-CD131

compounds or their mimetic pharmaceutical compositions

antibody (bottom panel). The arroWhead at the left of each
panel indicates the position of the IL-3RO. (CD123) and

described above.
In still another set of embodiments, the present invention

IL-3R[3 (CD131) chains, respectively.
50

FIGS. 5A, 5B and 5C shoW phosphorylation of signal
transduction components in response to IL-3. Three primary

cells from bone marroW. These stems cells may give rise to

AML samples (Lanes 1—3) Were derived from peripheral

leukemia progenitor cells, or they may be the progenitor
cells, Which may be impaired by the method of the invention
using various compounds or their mimetics and cytotoxic
agents that may be contacted to either a bone marroW sample 55
or injected into a bone marroW of an individual, thereby
destroying at least some of the leukemic stem cells in the

blood and sorted to isolate the CD34+ population. Samples
Were treated With (+) or Without (—) 20 ng/ml IL-3 for 15
minutes, then lysed and subjected to PAGE. Each gel Was
then electro-blotted and membranes Were probed With anti
bodies speci?c to either total or phosphorylated protein for
Akt (A), Stat5 (B), and Mek-1(C). The lane labeled C on

bone marroW.

each blot is an antibody control and is derived from NIH 3T3

provides a method of selectively purging leukemic stem

BRIEF DESCRIPTION OF THE DRAWINGS
60

The present invention Will become more fully understood

from the detailed description given herein beloW, and the
accompanying draWings Which are given by Way of illus
tration only, and thus are not limiting of the present
invention, and Wherein:
FIGS. 1A and 1B shoW CD123 expression on normal and

leukemic hematopoietic cells. Representative examples of

cells treated +/— 50 ng/ml PDGF (A and C), or TF-1 cells
treated +/— 25 ng/ml GM-SCF
FIGS. 6A, 6B and 6C shoW CD123 expression in primary
ALL. FloW cytometric analysis of CD123 expression on

three independent primary ALL (acute lymphoid leukemia)
specimens. CD123 labeling is shoWn by the ?lled (dark)
65

plots and controls are shoWn by open plots.
FIGS. 7A, 7B and 7C shoW CD123 expression in primary
CML. FloW cytometric analysis of CD123 expression on

US 6,733,743 B2
5

6

three independent primary CML (chronic myelogenous

lymphoma, such as multiple myeloma, non-Hodgkin’s
lymphoma, Burkitt’s lymphoma, and follicular lymphoma
(small cell and large cell), among others. For purposes of

leukemia) specimens. CD123 labeling is shoWn by the ?lled
(dark) plots and controls are shoWn by open plots.

this invention, at least some of the hematologic cancer cells
are characteriZed by cells that express CD123. Also, for the

DETAILED DESCRIPTION OF THE
INVENTION
De?nitions
As used herein, the term “antibody” means an immuno

globulin molecule, or a fragment of an immunoglobulin
molecule, having the ability to speci?cally bind to a par
ticular antigen. Antibodies are Well knoWn to those of

10

ordinary skill in the science of immunology. As used herein,
the term “antibody” means not only intact antibody mol
ecules but also fragments of antibody molecules retaining
antigen-binding ability. Such fragments are also Well knoWn
in the art and are regularly employed both in vitro and in
vivo. In particular, as used herein, the term “antibody”
means not only intact immunoglobulin molecules but also

purposes of this application, Whenever leukemia or malig
nant lymphoproliferative disorders are mentioned, the diag
nostic and treatment method of the invention applies gen
erally to hematologic cancer.
As used herein, the term “introducing” shall mean any
means of delivery, Whether in vivo or in vitro, including
simple contact.
As used herein, the term “mimetic” means a compound or
molecule Which mimics the three-dimensional structures of

15

a site on CD123 to Which a compound may bind, or the
compound may be a molecule that mimics a molecule that
binds to CD123. In the case of an anti-CD123 antibody
binding site, or paratope, or active site, “mimetic” means a

the Well-knoWn active fragments F(ab‘)2, Fab, Fv, Fd, VH
and VL.

compound that mimics the three-dimensional structure of
any combination of the antibody hypervariable loops or

As used herein, the terms “bind” or “bind(s)” shall mean
any interaction, Whether via direct or indirect means, Which

complementarity determining regions (CDR’s).

affects the speci?ed receptor or receptor subunit.
As used herein, the terms “binds selectively to” shall
mean that the compound, composition, formulation, etc.
does not signi?cantly bind IL3R beta chain, but does bind
IL3R alpha chain.
As used herein, the terms “CD123”, “IL3R subunit alpha”

dimensional placement of atoms of the mimetic such that
similar ionic forces, covalent forces, van der Waal’s or other

As used herein, the term “mimic” means the three

25

forces, and similar charge complementarity, or electrostatic
complementarity, eXist betWeen the atoms of the mimetic
and the atoms of the binding site of the compound such as
a peptide or an antibody such that the mimetic has a similar

and “IL3Rot” shall be used interchangeably to mean an

binding af?nity for CD123 as the parent compound and/or

antigenic determinant that is detectable in leukemia precur

such that the mimetic has a similar effect on the function of
CD123 in vitro or in vivo.

sor cells as described herein, but not detectable on normal
cells as described herein.

In the case of anti-CD123 antibodies, Within the antigen
binding portion of an antibody, as is Well-knoWn in the art,

As used herein, the term “compound” shall mean any

purity of active ingredient, including formulations,

there are complementarity determining regions (CDRs),

compositions, naturally-occurring plants or animals, etc.

Which directly interact With the epitope of the antigen, and
frameWork regions (FRs), Which maintain the tertiary struc
ture of the paratope. In both the heavy chain Fd fragment and
the light chain of IgG immunoglobulins, there are four

The compound may include molecules that are naturally

35

occurring, such as proteins, nucleic acids, single stranded
nucleic acids, lipids, carbohydrates, and antibodies.

frameWork regions (FR1 through FR4) separated respec
tively by three complementarity determining regions (CDR1

HoWever, synthetic versions of these naturally occurring
molecules may be made, so long as they bind CD123. The
compounds may comprise more than one component. For
example, a compound may be a monoclonal antibody

through CDR3). The CDRs, and in particular the CDR3
regions, and more particularly the heavy chain CDR3, are

largely responsible for antibody speci?city.

attached to a toXin. Or, it may be a lipid attached to a label.

The compounds may further comprise mimetics, and
aptamers, but Which all retain their speci?city to CD 123.
As used herein, the term “impair” shall mean any decrease

As used herein, the term “normal” means any non

pathogenic or non-pathology-related cells or conditions.

activity).

As used herein, the terms “primitive” and “progenitor”
shall be interchangeable.
As used herein, With respect to polypeptides and

As used herein, the term “hematologic cancer” refers to a
cancer of the blood, and includes leukemia and malignant

antibodies, the term “substantially pure” means that the
polypeptides are substantially free of other substances With

lymphoproliferative disorders, among others. “Leukemia”

Which they may be found in nature or in vivo systems to an

refers to a cancer of the blood, in Which too many White

eXtent practical and appropriate for their intended use. In
particular, the polypeptides are suf?ciently pure and are

45

in functionality or activity (including groWth or proliferative

blood cells that are ineffective in ?ghting infection are made,

thus croWding out the other parts that make up the blood,

suf?ciently free from other biological constituents of their

such as platelets and red blood cells. It is understood that

host cells so as to be useful in, for eXample, generating

cases of leukemia are classi?ed as acute or chronic. Cancer 55

antibodies, sequencing, or producing pharmaceutical prepa
rations. By techniques Well knoWn in the art, substantially
pure polypeptides may be produced in light of the nucleic

cells in acute leukemias are blocked at an immature stage.

HoWever, they continue to multiply. Consequently, there is
a large accumulation of non-functional immature cells and
the concomitant loss of functional cells. Chronic leukemias
progress more sloWly, With cancer cells developing to full

substantially puri?ed polypeptide of the invention may be

maturity. Furthermore, the White blood cells may be myel

pharmaceutical preparation, the polypeptide may comprise

ogenous or lymphoid. Thus, certain forms of leukemia may

genic leukemia (CML); and myelodysplastic syndrome.

only a small percentage by Weight of the preparation. The
polypeptide is nonetheless substantially pure in that it has
been substantially separated from the substances With Which
it may be associated in living systems.
As used herein With respect to compounds or mimetics,

“Malignant lymphoproliferative disorders” may refer to a

the term “substantially pure” means that the compounds are

acid and amino acid sequences disclosed herein. Because a

admiXed With a pharmaceutically acceptable carrier in a

be, by Way of eXample, acute lymphotic (or lymphoblastic)
leukemia (ALL); acute myelogenic leukemia (AML);
chronic lymphocytic leukemia (CLL); or chronic myelo

65

US 6,733,743 B2
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substantially free of other substances With Which they may

The invention also relates to a method for preparing

be found, in nature, in in vivo systems, or as a result of
chemical or other synthesis, to an extent practical and
appropriate for their intended use. In particular, the com

diagnostic or pharmaceutical compositions comprising the
CD123 binding compound and its mimetics. The pharma
ceutical preparation includes a pharmaceutically acceptable

pounds are suf?ciently pure and are suf?ciently free from
other biological constituents of their hosts cells, or chemical

carrier. Such carriers, as used herein, mean non-toxic mate
rials that do not interfere With the effectiveness of the

or physical constituents of their synthesis so as to be useful

biological activity of the active ingredients. The term

in, producing pharmaceutical preparations. By techniques

“physiologically acceptable” refers to a non-toxic material
that is compatible With a biological system such as a cell,
cell culture, tissue, or organism. The characteristics of the
carrier Will depend on the route of administration. Physi

Well knoWn in the art (US. Pat. No. 5,648,379; Colman, P.
G. Protein Science 3: 1687—1696, 1994; Malby, et al.,
Structure 2: 733—746, 1994; McCoy et al., J. Molecular
Biol. 268: 570—584, 1997), substantially pure compounds or
mimetics, may be designed. Because a substantially puri?ed
compound of the invention may be admixed With a phar
maceutically acceptable carrier in a pharmaceutical

10

ologically and pharmaceutically acceptable carriers include
diluents, ?llers, salts, buffers, stabiliZers, solubiliZers, and
other materials that are Well knoWn in the art.
15

preparation, the compound may comprise only a small
percentage by Weight of the preparation. The compound is
nonetheless substantially pure in that it has been substan
tially separated from the substances With Which it may be
associated in living, chemical or other systems.

20

Mimetics that Bind to CD123

Compounds that target CD123 can be found. Phage
display libraries can be used to determine the DNA encoding
the polypeptide that binds to CD123. The principles of this
approach are disclosed in US. Pat. No. 5,837,500, Which is

The anti-CD123 antibodies and mimetics may be labeled
by a variety of means for use in diagnostic and/or pharma
ceutical applications. There are many different labels and
methods of labeling knoWn to those of ordinary skill in the
art. Examples of the types of labels Which can be used in the
present invention include enZymes, radioisotopes, ?uores
cent compounds, colloidal metals, chemiluminescent

compounds, and bioluminescent compounds. Those of ordi
25

nary skill in the art Will knoW of other suitable labels for
binding to the CD123 binding compound, such as mono
clonal antibodies, or mimetics thereof, or Will be able to

incorporated by reference herein in its entirety. Other non

ascertain such, using routine experimentation. Furthermore,

peptide molecules that may bind to CD123 include nucleic

the binding of these labels to the CD123 speci?c compounds

acids, and liposomes. Carbohydrates may also be used to
target CD123. It is possible that the compound may not be
a naturally occurring biological molecule. Such chemicals

or their mimetics can be done using standard techniques
common to those of ordinary skill in the art.

may be made by combinatorial libraries Which are Well

In the case of antibodies, another labeling technique
Which may result in greater sensitivity consists of coupling

knoWn in the art, With the assay goal being the binding of the
chemical compound to CD123. Liposomes may ensconce

the antibodies or mimetics to loW molecular Weight haptens.
These haptens can then be speci?cally altered by means of

30

certain toxins or other cell-impairing substances or cell

imaging compounds may be used to target CD123. Numer

35

ous variations and combinations of compounds as targeting
agents are contemplated by the method of the invention, so

anti-hapten antibodies.
Diagnostic and Treament Kits

long as CD123 is targeted, With the knoWledge that leukemia
detection and leukemia treatment is kept in mind.
Mimetics of Anti-CD123 Antibodies
It is also possible to use the anti-idiotype technology to

a second reaction. For example, it is common to use haptens
such as biotin, Which reacts With avidin, or dinitrophenol,
pyridoxal, or ?uorescein, Which can react With speci?c

The materials for use in the assay of the invention are
40

ideally suited for the preparation of a kit. Such a kit may
comprise a carrier means being compartmentaliZed to

isolate or screen for compounds or mimetics Which mimic

receive in close con?nement one or more container means

an epitope. Thus, an anti-idiotypic monoclonal antibody
Which is the image of the epitope bound by the ?rst

such as vials, tubes, and the like, each of the container means
comprising one of the separate elements to be used in the

monoclonal antibody, since it effectively acts as an antigen,
may be used to isolate mimetics from a combinatorial
chemical, or other libraries, of chemical or other

method. For example, one of the container means may
comprise a compound that binds to CD123, such as a
monoclonal antibody, or a mimetic thereof, Which is, or can

compounds, such as peptide phage display libraries (Scott

be, detectably labeled With a label that is suitable for

and Smith, Science 249: 386—390, 1990; Scott and Craig,
Curr. Opin. Biotechnol. 5: 40—48, 1992; Bonnycastle et al.,
J. Mol. Biol. 258: 747—762, 1996). Hence, peptides or
constrained peptides mimicking proteins or other

45

diagnostic purposes or if treatment is desired, a cytotoxic or
50

comprising a reporter-means, such as a biotin-binding
protein, such as avidin or streptavidin, bound to a reporter
molecule, such as an enZymatic or ?uorescent label. In

compounds, including those With nucleic acid, lipid, carbo
hydrate or other moieties, may be cloned (Harris et al., Proc.

Natl. Acad. Sci. (USA) 94: 2454—2459, 1997).

impairing agent. In the case of a diagnostic kit, the kit may
also have containers containing buffer(s) and/or a container

55 addition to the chemical material, of course a means of

nature and are therefore more resistant to catabolism, excre

instructions for using the kit is included, preferably for either
diagnosing leukemia, or treating leukemia. The instruction

tion or degradation, may be designed by the three
dimensional placement of atoms, such that similar ionic

Written on a separate paper, or on the outside or inside of the

Purely synthetic molecules, Which may not occur in

forces, covalent forces, van der Waal’s or other forces, and

similar charge complementarity, or electrostatic
complementarity, exist betWeen the atoms of the mimetic
and the atoms of the antigenic binding site or epitope. These
mimetics may then be screened for high af?nity binding to
CD123 and detect and/or impair the CD123 bearing cell in

means may be Written on the vial, tube and the like, or
60

container. The instructions may also be in the form of a

multi-media format, such as CD, computer disk, video and
so on.

Preparation of Immunotoxins
While the preparation of immunotoxins is, in general,
65

Well knoWn in the art (see, e.g., US. Pat. No. 4,340,535, and

vitro or in vivo, as described in more detail beloW.

EP 44167, both incorporated herein by reference), the inven

Diagnostic and Pharmaceutical Preparations

tors are aWare that certain advantages may be achieved
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through the application of certain preferred technology, both

Once conjugated, it Will be important to purify the con

in the preparation of the immunotoxins and in their puri?
cation for subsequent clinical administration. For example,
While IgG based immunotoxins Will typically exhibit better
binding capability and sloWer blood clearance than their Fab‘
counterparts, Fab‘ fragment-based immunotoxins Will gen
erally exhibit better tissue penetrating capability as com
pared to IgG based immunotoxins.

jugate so as to remove contaminants such as unconjugatedA

Additionally, While numerous types of disul?de-bond
containing linkers are knoWn Which can successfully be

Examples beloW Which have been found to provide conju
gates to a suf?cient degree of purity to render them clinically
useful. In general, the most preferred technique Will incor

employed to conjugate the toxin moiety With the binding

chain or binding agent. It is important to remove unconju

gated Achain because of the possibility of increased toxicity.
Moreover, it is important to remove unconjugated binding
agent to avoid the possibility of competition for the antigen
betWeen conjugated and unconjugated species. In any event,
a number of puri?cation techniques are disclosed in the
10

agent, certain linkers Will generally be preferred over other
linkers, based on differing pharmacologic characteristics and
capabilities. For example, linkers that contain a disul?de
bond that is sterically “hindered” are to be preferred, due to

their greater stability in vivo, thus preventing release of the
toxin moiety prior to binding at the site of action.

15

exchange WithAchain binding to provide good separation of
conjugated from unconjugated binding.

Cross-linking reagents are used to form molecular bridges
that tie together functional groups of tWo different proteins
(e.g., a toxin and a binding agent). To link tWo different
proteins in a step-Wise manner, hetero bifunctional cross
linkers can be used Which eliminate the unWanted

The Blue-Sepharose alloWs the elimination of the free
20

(non conjugated) binding agent (e.g., the antibody or
fragment) from the conjugate preparation. To eliminate the
free (unconjugated) toxin (e.g., dgA) a molecular exclusion
chromatography step is preferred using either conventional
gel ?ltration procedure or high performance liquid chroma

homopolymer formation. An exemplary hetero bifunctional
cross-linker contains tWo reactive groups: one reacting With

primary amine group (e.g., N-hydroxy succinimide) and the
other reacting With a thiol group (e.g., pyridyl disul?de,

porate the use of Blue-Sepharose With a gel ?ltration or gel
permeation step. Blue-Sepharose is a column matrix com
posed of Cibacron Blue 3GA and agarose, Which has been
found to be useful in the puri?cation of immunoconjugates.
The use of Blue-Sepharose combines the properties of ion

25

maleimides, halogens, etc.). Through the primary amine

tography.
After a suf?ciently puri?ed conjugate has been prepared,

reactive group, the cross-linker may react With the lysine

one Will desire to prepare it into a pharmaceutical compo

residue(s) of one protein (e.g., the selected antibody or
fragment) and through the thiol reactive group, the cross
linker, already tied up to the ?rst protein, reacts With the

using for the last puri?cation step a medium With a suitable

sition that may be administered parenterally. This is done by
30

cysteine residue (free sulfhydryl group) of the other protein

Suitable pharmaceutical compositions in accordance With

(e.g., dgA).
The spacer arm betWeen these tWo reactive, groups of any
cross-linkers may have various lengths and chemical com
positions. A longer spacer arm alloWs a better ?exibility of

the invention Will generally comprise from about 10 to about
100 mg of the desired conjugate admixed With an acceptable
35

pharmaceutical diluent or excipient, such as a sterile aque
ous solution, to give a ?nal concentration of about 0.25 to

about 2.5 mg/ml With respect to the conjugate. Such formu
lations Will typically include buffers such as phosphate
buffered saline (PBS), or additional additives such as phar
maceutical excipients, stabiliZing agents such as BSA or

the conjugate components While some particular compo
nents in the bridge (e.g., benZene group) may lend extra
stability to the reactive group or an increased resistance of

the chemical link to the action of various aspects (e.g.,
disul?de bond resistant to reducing agents).

pharmaceutical composition.

The most preferred cross-linking reagent is SMPT, Which

HSA, or salts such as sodium chloride. For parenteral
administration it is generally desirable to further render such

is a bifunctional cross-linker containing a disul?de bond that

compositions pharmaceutically acceptable by insuring their

40

is “sterically hindered” by an adjacent benZene ring and

sterility, non-immunogenicity and non-pyrogenicity. Such

methyl groups. It is believed that stearic hindrance of the

techniques are generally Well knoWn in the art as exempli

disul?de bond serves a function of protecting the bond from 45 ?ed by Remington’s Pharmaceutical Sciences, 16th Ed.
attack by thiolate anions such as glutathione Which can be
Mack Publishing Company, 1980, incorporated herein by

present in tissues and blood, and thereby help in preventing
decoupling of the conjugate prior to its delivery to the site
of action by the binding agent. The SMPT cross-linking
reagent, as With many other knoWn cross-linking reagents,

reference. It should be appreciated that endotoxin contami
nation should be kept minimally at a safe level, for example,
less than 0.5 ng/mg protein. Moreover, for human
50

lends the ability to cross-link functional groups such as the

SH of cysteine or primary amines (e.g., the epsilon amino
group of lysine). Another possible type of cross-linker
includes the hetero-bifunctional photoreactive phenylaZides

A preferred parenteral formulation of the immunotoxins

containing a cleavable disul?de bond such as 55

sulfosuccinimidyl-2-(p-aZido salicylamido) ethyl-1,3‘
dithiopropionate. The N-hydroxy-succinimidyl group reacts
With primary amino groups and the phenylaZide (upon

the present invention Will involve the targeting of a toxin
60

Although the “hindered” cross-linkers Will generally be
preferred in the practice of the invention, non-hindered
linkers can be employed and advantages in accordance
hereWith nevertheless realiZed. Other useful cross-linkers,
not considered to contain or generate a protected disul?de,
include SATA, SPDP and 2-iminothiolane. The use of such
cross-linkers is Well understood in the art.

in accordance With the present invention is 0.25 to 2.5 mg
conjugate/ml in 0.15M NaCl aqueous solution at pH 7.5 to
9.0. The preparations may be stored froZen at —10° C. to
—70° C. for at least 1 year.

It is contemplated that most therapeutic applications of

photolysis) reacts non-selectively With any amino acid resi
due.

administration, preparations should meet sterility,
pyrogenicity, general safety and purity standards as required
by FDA Of?ce of Biological Standards.

moiety (cytotoxic agent) to the CD123 leukemia marker.
This is due to the much greater ability of most toxins to
deliver a cell killing effect as compared to other potential

agents.
65

HoWever, there may be circumstances such as When the
target antigen does not internaliZe by a route consistent With
ef?cient intoxication by immunotoxins, Where one Will
desire to target chemotherapeutic agents such as cytokines,

US 6,733,743 B2
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antimetabolites, alkylating agents, hormones, and the like.

ably labeled in various Ways. Examples of types of immu

The advantages of these agents over their non-antibody

noassays Which can utiliZe the monoclonal antibodies and

conjugated counterparts is the added selectivity afforded by
the antibody. One might mention by Way of example agents
such as steroids, cytosine arabinoside, methotrexate,

their mimetics are competitive and non-competitive immu
noassays in either a direct or indirect format. Examples of

such immunoassays are the radioimmunoassay (RIA) and
the sandWich (immunometric) assay. Detection of antigens

aminopterin, anthracyclines, mitomycin C, vinca alkaloids,
demecolcine, etopside, mithramycin, and the like. This list
is, of course, merely exemplary in that the technology for
attaching pharmaceutical agents to antibodies for speci?c
delivery to tissues is Well established.

10

One preferred cytotoxic moiety for use in the present

using the monoclonal antibodies and their mimetics can be
done utiliZing immunoassays Which are run in either the
forWard, reverse, or simultaneous modes, including immu
nohistochemical assays on physiological samples. Those of
skill in the art Will knoW, or can readily discern, other

invention is a radioisotope, Which can be coupled to or

immunoassay formats Without undue experimentation.

conjugated With, for example, an anti-CD123 antibody.

The compounds that bind CD123 and mimetics can be
bound to many different carriers and used to detect the

Preferred radioisotopes include ot-emitters such as, for

example, 211Astatine, 212Bismuth and 213Bismuth, as Well as

15

[3-emitters such as, for example, 131Iodine, QOYttrium,
177Lutetium, 153Samarium and 109Palladium. Particularly

glass, polystyrene, polypropylene, polyethylene, dextran,

preferred radioisotopes are 211Astatine and 131Iodine.
It is proposed that particular bene?ts may also be
achieved through the application of the invention to cell
imaging. Imaging of leukemia cells is believed to provide a

presence of CD123 bearing leukemia cells, including pro
genitor cells. Examples of Well-knoWn carriers include

nylon, amylase, natural and modi?ed cellulose,
polyacrylamide, agarose and magnetite. The nature of the
20

carrier can be either soluble or insoluble for purposes of the

major advantage When compared to available imaging

invention. Those skilled in the art Will knoW of other suitable
carriers for binding various compounds, or Will be able to

techniques, in that the cells are readily accessible.

ascertain such, using routine experimentation.

Moreover, the technology for attaching paramagnetic,
radioactive and even ?uorogenic ions to antibodies is Well
established. Many of these methods involve the use of a

25

metal chelate complex employing, for example, an organic
chelating agent such a DTPA attached to the antibody (see,
e.g., US. Pat. No. 4,472,509). In the context of the present
invention the selected ion is thus targeted to the cancerous

For purposes of the invention, CD123 may be detected by
the compounds and their mimetics When present in biologi
cal ?uids and tissues. Any sample containing a detectable
amount of CD123 ectopeptide can be used. Asample can be

a liquid such as urine, saliva, cerebrospinal ?uid, blood,
30

serum or the like; a solid or semi-solid such as tissues, feces,
or the like; or, alternatively, a solid tissue such as those

area by the antibody, alloWing imaging to proceed by means

commonly used in histological diagnosis.

of the attached ion.

In Vivo Detection of CD123

In a preferred embodiment, in the method of the

In using the CD123 binding compounds and mimetics for

invention, the antibodies may also be fused to a protein
effector molecule by recombinant means such as through the
use of recombinant DNA techniques to produce a nucleic
acid Which encodes both the antibody and the effector
molecule and expressing the DNA sequence in a host cell
such as E. coli. The DNA encoding the chimeric protein may
be cloned in cDNA or in genomic form by any cloning
procedure knoWn to those skilled in the art. See for example

the in vivo detection of CD123, the detectably labeled
35

diagnostically effective. The term “diagnostically effective”
means that the amount of detectably labeled compound,
such as monoclonal antibody or mimetic is administered in
40

Sambrook et al., Molecular Cloning: A Laboratory Manual,
Cold Spring Harbor Laboratory, (1989), Which is herein

incorporated by reference.
Fusion or conjugation of antibodies to various labels

compound or its mimetic is given in a dose Which is

45

produces a highly speci?c detectable marker that may be
used to detect the presence or absence of cells or tissues

bearing the particular molecule to Which the antibody is
detected. Alternatively, the antibodies may be chemically

suf?cient quantity to enable detection of the leukemia cells
for Which the compounds or mimetics are speci?c.
The concentration of detectably labeled compound or
mimetic Which is administered should be suf?cient such that
the binding to CD123 or CD123-bearing leukemia cells, is

detectable compared to the background. Further, it is desir
able that the detectably labeled compound or mimetic be
rapidly cleared from the circulatory system in order to give
the best target-to-background signal ratio.
As a rule, the dosage of detectably labeled compound or
mimetic for in vivo diagnosis Will vary depending on such

conjugated or fused to an effector molecule that is another 50 factors as age, sex, and extent of disease of the individual.

The dosage of the compound can vary from about 0.01

speci?c binding moiety, e. g. a ligand such as those described
above. In this form the composition Will act as a highly
speci?c bifunctional linker. This linker may act to bind and
enhance the interaction betWeen cells or cellular components

to Which the fusion protein binds. Thus, for example, Where

mg/kg to about 500 mg/kg, preferably about 0.1 mg/kg to
about 200 mg/kg, most preferably about 0.1 mg/kg to about
10 mg/kg. Such dosages may vary, for example, depending

the fusion protein is a groWth factor joined to an antibody or

on Whether multiple injections are given, on the tissue being
assayed, and other factors knoWn to those of skill in the art.

antibody fragment (eg an Fv fragment of an antibody), the
antibody may speci?cally bind antigen positive cancer cells

instrument available is a major factor in selecting an appro

While the groWth factor binds receptors on the surface of
immune cells. The fusion protein may thus act to enhance

55

For in vivo diagnostic imaging, the type of detection

60

and direct an immune response toWard target cancer cells.

In Vitro Detection and Diagnostics
The method of using the compounds that bind to CD 123
and their mimetics are suited for in vitro use, for example,

in immunoassays in Which they can be utiliZed in liquid
phase or bound to a solid phase carrier. In addition, the
monoclonal antibodies in these immunoassays can be detect

65

priate radioisotope. The radioisotope chosen must have a
type of decay Which is detectable for the given type of
instrument. Still another important factor in selecting a
radioisotope for in vivo diagnosis is that the half-life of the
radioisotope be long enough such that it is still detectable at
the time of maximum uptake by the target, but short enough
such that deleterious radiation With respect to the host is

acceptable. Ideally, a radioisotope used for in vivo imaging
Will lack a particle emission but produce a large number of

US 6,733,743 B2
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photons in the 140—250 keV range, Which may be readily

groWth factor, bacterial endotoxin or the lipid A moiety of
bacterial endotoxin. In any event, it is proposed that agents

detected by conventional gamma cameras.

For in vivo diagnosis, radioisotopes may be bound to the

such as these may be successfully conjugated to antibodies
in a manner that Will alloW their targeting, internalization,
release or presentation to blood components at the site of the

compound either directly or indirectly by using an interme
diate functional group. Intermediate functional groups
Which often are used to bind radioisotopes Which exist as
metallic ions are the bifunctional chelating agents such as

targeted leukemia cells as required using knoWn conjugation

technology.

diethylenetriaminepentacetic acid (DTPA) and
ethylenediaminetetra-acetic acid (EDTA) and similar mol
ecules. Typical examples of metallic ions Which can be
bound to the monoclonal antibodies and mimetics of the

In certain preferred embodiments, cytotoxic agents for
therapeutic application Will include generally a plant-,
10

fungus- or bacteria-derived toxin, such as an Achain toxins,

a ribosome inactivating protein, ot-sarcin, aspergillin,

invention are 111In, 97Ru, 67Ga, 68Ga, 72As, 89Zr, 99'"Tc, 1231

restirictocin, a ribonuclease, diphtheria toxin or pseudomo

and 201TI.
In the diagnosis method of the invention, the compounds

nas exotoxin, to mention just a feW examples. The use of
toxin-antibody constructs is Well knoWn in the art of
immunotoxins, as is their attachment to antibodies. Of these,
a particularly preferred toxin for attachment to antibodies
Will be a deglycosylated ricin A chain. Deglycosylated ricin

and mimetics can also be labeled With a paramagnetic 15

isotope for purposes of in vivo diagnosis, as in magnetic
resonance imaging (MRI) or electron spin resonance (ESR).
In general, any conventional method for visualiZing diag
nostic imaging can be utiliZed. Usually gamma and positron
emitting radioisotopes are used for camera imaging and
paramagnetic isotopes for MRI. Elements Which are par

A chain is preferred because of its extreme potency, longer
20

In other preferred embodiments, the cytotoxic agent may

ticularly useful in such techniques include 157Gd, 55Mn,
162Dy, 52Cr and 56Fe.

be a radioisotope. Preferred radioisotopes include ot-emitters

such as, for example, 211Astatine, 212Bismuth and

In the cell monitoring method of the invention, the
compounds and mimetics can be used in vitro and in vivo to
monitor the course of leukemia disease therapy. Thus, for

half-life, and because it is economically feasible to manu
facture a clinical grade and scale.

213Bismuth, as Well as [3-emitters such as, for example,
25

131Iodine, QOYttrium, 177Lutetium, 153Samarium and 109Pal
ladium.
As used herein, a “therapeutically effective amount” of a

example, by measuring the increase or decrease in the
biological molecules associated With such a diseases or

compound is a dosage large enough to produce the desired

changes in the concentration of CD123 ectopeptide or
CD123 bearing leukemia cells present in the body or in
various body ?uids, it Would be possible to determine
Whether a particular therapeutic regimen aimed at amelio

effect in Which the symptoms of leukemia or the likelihood
of onset of leukemia is decreased. Atherapeutically effective

30

amount is not, hoWever, a dosage so large as to cause

adverse side effects, such as hyperviscosity syndromes,

pulmonary edema, congestive heart failure, and the like.

rating the above leukemia disease is effective.
Prophylaxis and Therapy of Leukemia
The CD123 speci?c compounds can also be used thera
peutically for treatment of leukemia in both humans and
other animals. The term, “therapeutically” or “therapy” as
used herein in conjunction With the method of the invention
is directed to using CD123 binding compounds, such as
anti-CD123 monoclonal antibodies and their mimetics,
Which denotes both prophylactic as Well as therapeutic
administration and both passive immuniZation With substan

tially puri?ed polypeptide products, and mimetics, as Well as
gene therapy by transfer of polynucleotide sequences encod
ing the product or part thereof. Thus, the compounds and

35

skill in the art. The dosage may be adjusted by the individual
physician or veterinarian in the event of any complication.
A therapeutically effective amount may vary from about
40

0.01 mg/kg to about 500 mg/kg, preferably from about 0.1
mg/kg to about 200 mg/kg, most preferably from about 0.2
mg/kg to about 20 mg/kg, in one or more dose administra
tions daily, for one or several days.

45

mimetics can be administered to high-risk subjects in order
to lessen the likelihood and/or severity of leukemia relapse,
or administered to subjects already evidencing active leu

In the method of the invention, the compounds and their
mimetics can be administered by injection or by gradual
infusion over time. The administration of the compounds

and their mimetics may be, for example, intravenous,
intraperitoneal, intramuscular, intracavity, subcutaneous, or

kemia disease.

For certain applications, it is envisioned that pharmaco

Generally, a therapeutically effective amount may vary With
the subject’s age, condition, and sex, as Well as the extent of
the disease in the subject and can be determined by one of

transdermal.
50

logic agents Will serve as useful agents for attachment to the

Preparations for parenteral administration include sterile
aqueous or non-aqueous solutions. suspensions, and emul

compounds, particularly cytotoxic or otherWise anticellular

sions. Examples of non-aqueous solvents are propylene

agents having the ability to kill or suppress the groWth or cell
division of leukemia cells. In general, the invention con
templates the use of any pharmacologic agent that can be
conjugated to a CD123 binding compound and delivered in
active form to the targeted cell. Exemplary anticellular

glycol, polyethylene glycol, vegetable oils such as olive oil,
and injectable organic esters such as ethyl oleate. Aqueous
carriers include Water, alcoholic/aqueous solutions, emul

55

sions or suspensions, including saline and buffered media.
Parenteral vehicles include sodium chloride solution, Ring

agents include chemotherapeutic agents, radioisotopes as

er’s dextrose, dextrose and sodium chloride, lactated Ring

Well as cytotoxins. In the case of chemotherapeutic agents,

er’s or ?xed oils. Intravenous vehicles include ?uid and

the inventors propose that agents such as a hormone such as

60

a steroid; an antimetabolite such as cytosine arabinoside,

?uorouracil, methotrexate or aminopterin; an anthracycline;

mitomycin C; a vinca alkaloid; demecolcine; etoposide;
mithramycin; calicheamicin, CC-1065 and derivatives

nutrient replenishers, electrolyte replenishers (such as those
based on Ringer’s dextrose), and the like. Preservatives and
other additives may also be present such as, for example,

antimicrobials, anti-oxidants, chelating agents, and inert

melphalan, Will be particularly preferred. Other embodi

gases and the like.
Depending on the speci?c clinical status of the disease,
administration can be made via any accepted systemic

ments may include agents such as a coagulant, a cytokine,

delivery system, for example, via oral route or parenteral

thereof, or an alkylating agent such as chlorambucil or 65
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(—)/HLA-DR-. Blood 1998, 92: 4325—35). Furthermore,

route such as intravenous, intramuscular, subcutaneous or
percutaneous route, or vaginal, ocular or nasal route, in

there is evidence suggesting that such cells may be relatively
resistant to chemotherapeutic drugs, and consequently con

solid, semi-solid or liquid dosage forms, such as for

example, tablets, suppositories, pills, capsules, poWders,

tribute to the phenomenon of relapse (Terpstra W, et al.,
Fluorouracil selectively spares acute myeloid leukemia cells
With long-term groWth abilities in immunode?cient mice

solutions, suspensions, cream, gel, implant, patch, pessary,
aerosols, collyrium, emulsions or the like, preferably in unit
dosage forms suitable for easy administration of ?xed dos
ages. The pharmaceutical compositions Will include a con
ventional carrier or vehicle and a CD123 binding compound

and in culture. Blood 1996, 88: 1944—50). Thus, a better
understanding of LSC biology and the characteriZation of
unique LSC antigens are essential to the development of

and, in addition, may include other medicinal agents, phar

better treatments for AML.

While the various AML subtypes display considerable

maceutical agents, carriers, adjuvants, and so on.

diversity With respect to developmental characteristics,
phenotype, cytokine responsiveness, etc., there appears to be

If desired, the pharmaceutical composition to be admin
istered may also contain minor amounts of non-toxic aux

iliary substances such as Wetting or emulsifying agents, pH
buffering agents and the like, such as for example, sodium
acetate, sorbitan monolaurate, triethanolamine oleate, and so

15

on.

The compounds of this invention are generally adminis
tered as a pharmaceutical composition Which comprises a
pharmaceutical vehicle in combination With a CD123 bind
ing compound. The amount of the drug in a formulation can

lish leukemia in NOD/SCID mice (Bonnet D, et al., Human
acute myeloid leukemia is organiZed as a hierarchy that

originates from a primitive hematopoietic cell. Nat. Med.
1997, 3: 730—737). Similar studies by others have corrobo

vary Within the full range employed by those skilled in the
art, e.g., from about 0.01 Weight percent (Wt %) to about
99.99 Wt % of the drug based on the total formulation and
about 0.01 Wt % to 99.99 Wt % excipient.

a marked degree of functional conservation at the level of
more primitive leukemic cells. This feature has been dem
onstrated by the Work of Bonnet et. al., in Which a CD34+/
CD38- subpopulation Was shoWn to be suf?cient to estab

rated the existence of leukemic stem cells for both AML and

25

The preferred mode of administration, for the conditions
mentioned above, is oral administration using a convenient
daily dosage regimen Which can be adjusted according to the
degree of the complaint. For said oral administration, a

pharmaceutically acceptable, non-toxic composition is

CML and con?rmed their relatively homogeneous pheno
type and functional capacity (Blair A, Hogge e tal., Most
acute myeloid leukemia progenitor cells With long-term
proliferative ability in vitro and in vivo have the phenotype
CD34(+)/CD71(—)/HLA-DR-. Blood 1998, 92: 4325—35;
Holyoake T, et al., Isolation of a highly quiescent subpopu
lation of primitive leukemic cells in chronic myeloid leu

contain betWeen about 0.01 Wt % and 99.99 Wt % of the

kemia. Blood 1999, 94: 2056—64). HoWever, to date, no
study has identi?ed an antigenic feature of myeloid LSC’s
that may alloW their identi?cation or preferential targeting
for ablative therapy. In this report, We have identi?ed an
additional commonality among CD34+/CD38— AML stem
cells, expression of CD123, Which facilitates their discrimi
nation from normal hematopoietic stem cells. While the
CD123 antigen Was readily detected at high levels on AML
cells, the IL-3 receptor [3 chain, CD131, Was not detected.
Our experiments indicate that the transcription factor

active compound according to this invention.

IRF-1 (Interferon regulatory factor-1) is over-expressed (in

formed by the incorporation of the selected CD123 binding
compound in any of the currently used excipients, such as,

for example, pharmaceutical grades of mannitol, lactose,
starch, magnesium stearate, sodium saccharine, talc,
cellulose, glucose, gelatin, sucrose, magnesium carbonate,

35

and the like. Such compositions take the form of solutions,

suspensions, tablets, pills, capsules, poWders, sustained
release formulations and the like. Such compositions may

6 of 6 primary AML specimens examined). Previous studies

Preferably the compositions Will have the form of a sugar
coated pill or tablet and thus they Will contain, along With the
active ingredient, a diluent such as lactose, sucrose, dical
cium phosphate, and the like; a disintegrant such as starch or
derivatives thereof; a lubricant such as magnesium stearate
and the like; and a binder such as starch,

by Korpelainen et. al. have shoWn that treatment of endot
helial cells With IFN-y results in up-regulation of CD123
45

(Korpelainen E I, et al., Interferon-gamma upregulates
interleukin-3 (IL-3) receptor expression in human endothe
lial cells and synergiZes With IL-3 in stimulating major

histocompatibility complex class II expression and cytokine

polyvinylpyrrolidone, acacia gum, gelatin, cellulose and
derivatives thereof, and the like.
It is understood that by “pharmaceutical composition”, it
is meant that the CD123 binding compound is formulated

production. Blood 1995, 86: 176—82). Similarly, our oWn
studies have shoWn that treatment of primary AML cells

diagnosing or treating leukemia in the individual. And, by

With IFN-y increases expression of CD123 (data not shoWn).
Thus, aberrant expression of interferon regulatory molecules
might play a role in controlling CD123 expression in AML

“pharmaceutical composition”, it excludes those composi

cells.

into a substance that is to be administered purposefully

tions that are used to administer to individuals as test
Expression of the CD123 antigen formally demonstrates
compounds for a purpose other than as a diagnostic or 55 that LSC’s are biologically distinct from their normal stem

treatment agent for leukemia.
The invention is described in further detail hereinbeloW.
Several recent studies have suggested the presence and

normal hematopoietic stem cells, it provides a unique

importance of stem cells in both the genesis and perpetua

feature may be useful for research purposes, as Well as in

tion of AML. Phenotypically, cells described as CD34+/

minimal residual disease (MRD) studies. Further, the
CD123 epitope represents a target to Which therapeutic

cell counterparts. Because CD123 is not readily found on

marker that can be used to identify malignant tissue. This

CD38- or CD34+/HLA-DR- appear to play a central role in

the development of leukemic populations (Bonnet D, et al.,

strategies may be directed. Previous clinical trials have used
monoclonal antibodies against both the CD33 and CD45

Human acute myeloid leukemia is organiZed as a hierarchy

that originates from a primitive hematopoietic cell. Nat.
Med. 1997, 3: 730—737; Blair A, et al., Most acute myeloid

leukemia progenitor cells With long-term proliferative abil
ity in vitro and in vivo have the phenotype CD34(+)/CD71

antigens as a means to deliver radioisotopes to AML cells in
65

vivo (Appelbaum F R., Antibody-targeted therapy for
myeloid leukemia. Semin Hematol 1999, 36: 2—8.). In
addition, several other recent studies have shoWn exciting

US 6,733,743 B2
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results using monoclonal antibodies speci?c to antigens on
malignant cells such as CD20, CD52, and Her-2 (Maloney

CD123 antigen. For each specimen 50,000—100,000 events
Were analyZed. Using this approach, human cells could

D G., Advances in immunotherapy of hematologic malig
nancies. Curr Opin Hematol 1998; 5: 237—43; Sikic B I.,

reliably be detected to a frequency as loW as 0.1%. Any

NeW approaches in cancer treatment. Ann Oncol 1999, 10
Suppl 6: 149—53). Antibodies to CD123 may be useful in a

negative.

analysis falling beloW 0.1% positive cells Was considered

Example 3

similar paradigm and Will be capable of delivering a cyto
toxic hit that speci?cally targets the leukemic stem cell

Immunoblots

population.
We have shoWn that CD 123 represents a unique antigenic
marker for the identi?cation of primitive leukemic cells

10

from a broad range of human specimens across a broad

range of leukemic diseases. Our studies shoW that CD123 is

(Na3VO4), 30 pl aprotinin (Sigma), 1 mM phenylmethyl
sulfonyl ?uoride (Sigma), 1 pig/ml pepstatin, and 1 pig/ml

generally expressed at high levels and may be indicative of

previously uncharacteriZed aspects of leukemia biology.

15

The present invention Will be further illustrated in the

folloWing, non-limiting Examples. The Examples are illus
trative only and do not limit the claimed invention regarding
the materials, conditions, process parameters and the like
recited herein.

20

PAGE (Novex, 4—12% Bis-Tris or 7% Tris-Acetate gels)

using the equivalent of 4><105 cells per lane. FolloWing
25

blood or bone marroW of patients. Normal bone marroW Was

obtained as Waste material folloWing pathological analysis,

Were used. For the analysis of Mek and Akt, protein-speci?c
30

Research Interchange (NDRI). MarroW cells Were depleted
of erythrocytes by suspending in 150 mM NH4Cl+10 mM
NaHCO3 for 5 minutes, folloWed by tWo Washes With
phosphate buffered saline (PBS). Blood cells Were subjected

and phosphoprotein-speci?c rabbit polyclonal antibodies
from NeW England Biolabs Were used. Anti-Stat5 polyclonal

(Transduction Labs) and anti-phospho-Stat5 (NeW England
Biolabs) Were used to analyZe the phosphorylation status of
Stat5. All primary antibodies Were detected using alkaline
35

isolate the mononuclear White blood cell compartment.
Resulting leukocytes from marroW or blood Were then used

phosphatase-conjugated secondary antibodies (Santa CruZ
Biotechnology) and the ECF reagent (Pharmacia Biotech)
per manufacturer’s instructions. Blots Were visualiZed using
a Molecular Dynamics STORM 860 system and

for immunoaf?nity selection, and/or ?oW cytometric analy
sis or sorting. For CD34+ cell selection, the Miltenyi immu
noaf?nity device (varioMACS) Was used according to the

electrophoresis, samples Were electro-transferred onto

Immobilon-P membrane (Millipore) and probed With the
indicated antibodies. To detect CD123 (IL-3R alpha chain),
antibodies S-12 (Santa CruZ Biotech) or 9E5 (Pharmingen)

Primary AML cells Were obtained from the peripheral

to Ficoll-Paque (Pharmacia) density gradient separation to

and reducing agent (Novex, San Diego, Calif., per manu

Samples Were then immediately analyZed by denaturing

Example 1

surgical marroW harvest, or from the National Disease

leupeptin (Oncogene Research); incubated on ice for 30
minutes, and centrifuged at 15,000 xg for 10 minutes to
remove debris. The resulting protein lysate Was then ali
quoted and stored at —80° C. For immunoblot analysis,
protein lysates Were thaWed and mixed With sample buffer
facturer’s instructions), and heated at 70° C. for 10 minutes.

EXAMPLES

Materials and Methods: Cell Processing

Cell samples Were lysed at a concentration of 2><107

cells/ml in PBS containing: 1% NP-40, 0.5% deoxycholate,
0.1% sodium dodecyl sulfate (SDS), 1 mM sodium vanadate

ImagequantTM SoftWare.
40

Example 4

manufacturer’s instructions. In some cases, leukocytes Were

cryopreserved at a concentration of 5><107 cells/ml in freeZ

NOD/SCID Mouse Assays

ing medium consisting of Iscoves modi?ed Dulbecco
medium (IMDM), 40% fetal bovine serum (FBS) and 10%

dimethylsulfoxide (DMSO).

45

NOD/SCID mice (Jackson Laboratories, Bar Harbor,
Me.) Were exposed to 225 rads of y-irradiation from a 137Cs

Example 2

source. Cells to be assayed Were resuspended in 0.25 mls

FloW Cytometry
Cytokine receptors Were detected by labeling With the
folloWing monoclonal antibodies: CD114-biotin, CD116

sorted populations, 1><106 irradiated (2500 Rads) mouse

HBSS (Hanks balanced salt solution, Gibco) With 2% FBS
and injected IV into the tail vein. For the analysis of some
50

FITC, CD123-PE, CD131-biotin (all from Pharmingen),
CD117-PE (Coulter), and CD135-PE (Caltag). Biotinylated

lyZed for the presence of human cells using ?oW cytometry

(see above).

antibodies Were visualiZed by subsequent labeling With

streptavidin-PE (SA-PE, Becton Dickinson). Primitive AML

bone marroW cells Were co-injected as carrier. After 6—8
Weeks, animals Were sacri?ced and bone marroW Was ana

55

Example 5

subpopulations Were identi?ed using CD34-FITC or CD34

Results

PE in combination With CD38-APC (Becton Dickinson).
Primary AML cells Were identi?ed in NOD/SCID mice

using CD45-PE (Pharmingen) speci?c to human cells. To
analyZe cells transplanted into NOD/SCID mice, bone mar
roW Was harvested at 6—8 Weeks post-transplantation. Cells

Were blocked With the anti-Fc receptor antibody 2.4G2 and

25% human serum, folloWed by double-labeling With
human-speci?c CD34-FITC and CD45-PE antibodies. Con

Analysis of cytokine receptors demonstrates strong
60

expression of CD123 on primitive leukemic but not normal
cells. Multiparameter ?oW cytometry Was used to analyZe

the expression of cytokine receptors previously implicated
in the groWth of malignant hematopoietic cells. While

several receptors displayed interesting patterns of antibody

labeling, the most striking feature observed Was a remark
trol samples consisted of marroW cells from non 65 ably high and Well-conserved level of CD123 (IL-3R alpha
transplanted mice. In some cases, cells Were also labeled
chain) expression amongst primary AML specimens. FIG. 1
With CD123-PE to ensure sustained expression of the
shoWs representative examples of CD123 labeling in normal

US 6,733,743 B2
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and leukemic tissue. In FIG. 1A total normal marrow, as Well
as more primitive subsets, are shown With respect to CD123

in parallel. The data in FIG. 3 are a representative example
of one specimen that shoWed strong engraftment of leuke
mic cells at six Weeks post-engraftment. Panel AshoWs total
bone marroW cells labeled With antibodies speci?c to human

expression. Total marroW generally has about 7% positive
cells for CD123, but only about 1% of the population
expresses the antigen at high levels (see inset FIG. 1A). The
CD34+ population of normal marroW also has readily evi

CD34 and CD45. The How cytometric pro?le clearly indi
cates that a large population of human cells (CD45+) is
present in the marroW. In addition, the population is divided

dent CD123 expression (12% in FIG. 1A, right histogram),
as Would be expected for a population knoWn to contain

betWeen CD34+ and CD34- subsets, similar to the propor

hematopoietic progenitors. The labeling pro?le shoWn is in

tions of CD34 labeling seen in the original leukemic speci

good agreement With previous studies by Sato et. al. that

men. Panel B shoWs the same marroW sample gated only on
the CD45+ cells. The data indicate that all of the cells that

have also examined IL-3RO. levels on human CD34+ cells

(Sato N, et al., Expression and factor-dependent modulation
of the interleukin-3 receptor subunits on human hematopoi
etic cells. Blood 1993, 82: 752—61.). HoWever, the more

primitive CD34+/CD38- compartment shoWs no signi?cant
expression of CD123 (<1%). In contrast, primary AML cells
(FIG. 1B) displayed high levels of CD123. In both the

15

overall CD34+ population, as Well as the more primitive

CD34+/CD38- compartment, greater than 99% of the cells
Were positive for CD123. FIG. 2 shoWs ?ve additional

examples of CD123 labeling on CD34+/CD38- AML cells,

further demonstrating the strong expression of this antigen
on leukemic populations. Table 1 summariZes the experi
ments performed to date on the AML cell type, and shoWs

CD123 levels for primitive cells of AML subtypes M1, M2,
and M4. Of the 18 primary AML specimens examined,

25

CD123 Was strongly expressed on the primitive leukemia
cells in all but tWo instances. The tWo samples Which had
loWer CD 123 levels (samples AML-11 and AML-14, Table
1) both displayed a uniform shift in CD123 expression, but
had an overall labeling intensity that Was dimmer than most

have proliferated in vivo are CD123 positive. Table 2
summariZes the data for the three specimens tested. In all
cases, the CD123+ cells Were capable of engrafting the
NOD/SCID animals. Moreover, in all but one instance, the
CD123- populations did not contribute to in vivo repopu
lation. Thus, as de?ned by the NOD/SCID model, We
conclude that CD123 is expressed on the LSC.
Finally, as an independent means of con?rming the leu
kemic origin of CD123 positive cells, ?oW cytometry Was
used to sort CD34+/CD123+ cells from tWo leukemic speci
mens. These samples Were cultured for four days, synchro

niZed and then harvested for cytogenetic analysis. Exami
nation of spreads from each specimen shoWed that 20 out of
20 metaphases Was positive for the leukemia-speci?c trans
location.

Example 7
Biological Role of CD123 Expression in Leukemia

samples assayed. In many cases (9 of 18), CD123 negative

Cells.

cells Were virtually undetectable (0% or less than 1%).

To further corroborate the data obtained by ?oW
cytometry, immunoblot studies Were performed to analyZe

Conversely, expression of CD123 Was not detected on 3 of

5 normal samples of CD34+/CD38- cells and Was barely
detectable in tWo additional specimens (<1%). These How
cytometric analyses Were con?rmed using tWo different

IL-3R signal transduction components. For these studies,

anti-CD123 monoclonal antibodies to insure that the results

each AML sample Was derived from a peripheral blood
specimen and Was sorted to isolate the CD34+ population,

Were not an artifact caused by the use of a particular

thus insuring a virtually pure leukemic sample. First, expres

antibody.

sion of both the IL-3RO. and [3 chains Were examined. With

35

respect to CD123, the data shoWn in FIG. 4 (top panel)
clearly demonstrate expression in all leukemic samples

The high level of CD123 expression found on all AML

subtypes examined implies that IL-3RO. might play a central
role in creating or maintaining the leukemic state. To form

assayed. The CD34+ cells derived from normal marroW

the high af?nity receptor for IL-3, both the 0t and [3 chains
(CD123 and CD131 respectively) are necessary. Thus,
expression of CD131 Was also examined by How cytometry

(lane 2, CD34+) also shoW a Weak signal. This is consistent

on the AML specimens. Interestingly, While some expres
sion Was seen in bulk AML populations, in 15 of 15

45

specimens CD131 Was never detected in the CD34+ com

partment (data not shoWn).
Further data demonstrating CD123 expression in primary
ALL and primary CML cells, as Well as non-Hodgkin’s
lymphoma, are discussed in Examples 8 and 10.

population corroborates the strong signal seen by How
cytometry for AML cells. Another point to note is that the
molecular Weight of the CD123 band appears to vary

Example 6
In Vivo Engraftment Properties of Human CD123+
Leukemia Cells in NOD/SCID Mice.

With the data in FIG. 1A, Which shoW that normal CD34+
cells often contain a small subset of CD123+ cells. HoWever,
CD123 expression Was not detected by How cytometry in the
more primitive CD34+/CD38- subset of normal cells (FIG.
1A and Table 1). Due to their loW frequency, it Was not
possible to obtain suf?cient CD34+/CD38- cells of either
normal or AML origin for direct analysis by immunoblot.
Nonetheless, detection of a clear signal in the overall CD34+

55

slightly betWeen AML samples. We have performed
RT-PCR ?ngerprint analyses of the same specimens and
seen no obvious aberrancies (data not shoWn). Thus, it

appears that varying degrees of post-translational modi?ca

Given the strong CD123 expression observed on the vast

tion are the most likely explanation for this observation.
Consistent With the results obtained by How cytometry,
expression of CD131 Was not detected (FIG. 4, bottom

majority of cells that phenotypically encompass the LSC
population, it appeared likely that CD123 Would be useful as
a marker of LSC’s. Therefore, to establish the functional

panel).

capacity of CD 123+ cells, transplantation studies using the
NOD/SCID mouse model system Were performed. Three

To begin exploring a potential functional role for CD123,

primary AML specimens (AML-2, 5, and 15 from Table 1)
Were assayed by ?oW cytometrically sorting CD34+/

We examined the response of primary AML cells to IL-3.

CD123+ cells and transplanting them into irradiated NOD/
SCID mice. In addition, the remaining cells in the popula
tion (CD34—/CD123+/—) Were also sorted and transplanted

65

Typically, stimulation of hematopoietic cells With IL-3 leads
to several Well-characterized intracellular signal transduc

tion events (Hara T, et al., Function and signal transduction
mediated by the interleukin 3 receptor system in hemato

US 6,733,743 B2
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poiesis. Stem Cells 1996, 14: 605—18). Prevalent among

expression of CD123. This is the most common form of

these events are phosphorylation of Mek-1, Akt, and Stat-5

non-Hodgkin’s lymphoma. Thus, in a B-cell derived cancer,
expression of CD123 is consistent With the observation that
CD123 Was also observed on ALL cells (i.e. another type of
B cell cancer). This observation directly identi?es B cell
lymphomas as a target for therapies and diagnostics using

(Songyang Z, et al., Interleukin 3-dependent survival by the
Akt protein kinase. Proc Natl Acad Sci USA 1997, 94:

11345—50; YagisaWa M, et al., Signal transduction pathways
in normal human monocytes stimulated by cytokines and
mediators: comparative study With normal human neutro

CD123.

phils or transformed cells and the putative roles in function

ality and cell biology. Exp Hematol 1999, 27: 1063—76;
Sutor S L, et al., Aphosphatidylinositol 3-kinase-dependent
pathWay that differentially regulates c-Raf and A-Raf. J Biol
Chem 1999, 274: 7002—10; de Groot R P, et al., Regulation
of proliferation, differentiation and survival by the IL-3/IL

10

Those skilled in the art Will recogniZe, or be able to
ascertain using no more than routine experimentation, many

5/GM-CSF receptor family. Cell Signal 1998, 10: 619—28).
Consequently, immunoblot studies Were performed on these

All of the cited references are incorporated by reference
herein in their entirety.
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proteins to assess the degree of phosphorylation, both in the

equivalents to the speci?c embodiments of the invention
speci?cally described herein. Such equivalents are intended
to be encompassed in the scope of the folloWing claims.

presence or the absence of IL-3 stimulation. The data, shoWn
in FIG. 5, shoW no detectable phosphorylation of Akt and
Stat5 in the absence of IL-3, and only a moderate level of

phosphorylation for Mek-1. Furthermore, in response to
IL-3 stimulation, no appreciable increase in phosphorylation
is seen for any of the proteins assayed. These results suggest
that CD123 present on the surface of primary AML cells
does not contribute signi?cantly to signal transduction via
conventional IL-3 mediated pathWays.

TABLE 1
Expression of CD123 in Primitive Leukemic and
Normal Cells.

20

% CD123+ cells in

Specimen
AML

CD123 Expression in Primary ALL and Primary
30

Similar experimental protocol as described in Examples 1
through 4 Were folloWed, and the expression of CD123 Was

assayed in primary ALL and primary CML cells by flow
cytometry. The results Were consistent With the results

obtained With expression of CD123 in primary AML in
Example 5. FIGS. 6A, 6B, and 6C shoW reproducibly that
the primary ALL cells express CD123. Moreover, FIGS. 7A,
7B, and 7C shoW reproducibly that the primary CML cells

35

also express CD123.

AML-1

MDS/AML

100%

AML-2
AML-3
AML-4
AML-5
AML-6
AML-7
AML-8
AML-9

M1
M1
M4
M2
M4
nd
M4
M4

100%
95.2%
98.1%
99.7%
99.5%
100%
99.7%
99.8%

AML-10
AML-11
AML-12
AML-13
AML-14
AML-15
AML-16
AML-17
AML-18

M2
MDS/AML
nd
M1
M4
M4
M1
M1
M4

100%
70.2%
92.5%
97.5%
51.1%
98.1%
95.3%
98.9%
100%

40

Normal MarroW

45

BM-1
BM-2
BM-3
BM-4
BM-5

Example 9

CD123 Targeted Complement-Kill Assay
By using a complement-kill assay, “Current protocols in

CD34+/CD38- population

25

Example 8
CML Cells

FAB

na
na
na
na

0
<1%
0
0
<1%

na

Immunology” Edited by John Coligan, Ada Kruisbeek,
FAB = French, American, British classi?cation system
MDS/AML = myelodysplastic syndrome progressing to AML

David Margulies, Ethan Shevach, and Warren Strober, John

Wiley and Sons publishing, 1992, Which is incorporated by
reference herein in its entirety, this experiment demonstrates
that CD123+ cells are preferentially targeted. In this
experiment, We compared a typical AML specimen (i.e.

na = not applicable

50

TABLE 2

CD123+) to a normal bone marroW sample. For each speci
Engraftment of CD123+ Populations in NOD/SCID Mice.

men there is an untreated control, a sample treated With

complement alone, and a sample treated With anti-CD123+
complement. As shoWn in Table 3, there is a substantial

55

Population Assayed
Exp. Specimen (N)

Cells Inj ./

% CD45+ cells/

mouse

recip.

complement-killing effect on the AML specimen, but no
effect on the normal marroW. This is true for both the overall
sample, as Well as the more primitive CD34+ cells.

1

AML-2

CD34+/CD123+ (3)

4.9 x 10e6

2

AML-5

CD34+/CD123+ (4)

2.5 x 10e6

Accordingly, this experiment demonstrates that there is a
difference betWeen the effect on normal and leukemic cells

60

With respect to the speci?city for CD123.

Example 10
CD123 Expression in Lymphoma Cells.
Immunohistochemical analysis of tissue sections shoWed

that “diffuse large B cell lymphoma” is strongly positive for

65

42%
18%
67%
nd
0.2%
0.1%
15%
6%
1%
12%
nd
nd
nd

